New immune cell therapy trial for advanced cancers withdrawn before starting
NCT ID NCT06626256
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, grown in a lab, and then given back to help fight the cancer. The study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.